SenzaGen H2 2022: In the right direction - Redeye

Redeye provides an update in relation to SenzaGen’s H2 2022 report. We believe the year has been strong; sales came in a bit lower than our estimates; however, EBIT is better. We have chosen to only make minor changes in our estimates for the following years; however, following an updated Redeye rating, we change the WACC from 14.5% to 13.5%, resulting in a new fair value range with a base case of SEK21 (18).

Länk till analysen i sin helhet: https://www.redeye.se/research/879219/senzagen-h2-2022-in-the-right-direction?utm_source=finwire&utm_medium=RSS